Multiple NIH institutes, including NIAAA and NIDA, have invested tens of millions in clinical trials studying GLP-1 receptor agonists for substance use disorders, including alcohol addiction
Probes targeting GLP-1R (catalog 418851-C3), vGAT (catalog 319191-C3), vGluT2 (catalog 319171), somatostatin (Sst
Pharmaceutical giants like Lilly and Novo Nordisk are ramping up production to meet this demand, investing billions in capacity expansion
The flexibility of GLP-1 receptor modeling allows for wide use across disciplines, but the core structure is most often applied in metabolic pathway research, including insulin signaling, glucose transport simulation, and feeding behavior modeling in preclinical environments
Similarly, Eli Lilly highlighted on August 8 that progress on supply has bolstered their outlook, but that the end pharmacy experience will continue to be choppy. The FDAs Drug Shortage List The GLP-1 shortage began in March 2022, with semaglutide injection (the active pharmaceutical ingredient in Ozempic and Wegovy) first appearing on the FDAs shortage list , followed by tirzepatide injection (the active pharmaceutical ingredient in Mounjaro and Zepbound) in December 2022
There are no drugs specifically approved to treat the core genetic cause or the full spectrum of symptoms associated with Prader-Willi syndrome (PWS)
